SOURCES SOUGHT
R -- TRND Malaria Williamson Profiling from lead optimization and safety profiling panels
- Notice Date
- 6/26/2018
- Notice Type
- Sources Sought
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- NIHDA201800280
- Archive Date
- 7/21/2018
- Point of Contact
- Hunter A Tjugum, Phone: 3018275304
- E-Mail Address
-
hunter.tjugum@nih.gov
(hunter.tjugum@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION This is a Small Business Sources Sought (SBSS) notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability and type of qualified Small Business companies technically capable of meeting this potential government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. The notice is strictly for research and information purposes only. The information requested will assist the Government in determining the appropriate acquisition method including small business socio-economic set-aside possibilities and to determine the availability of qualified Small Business companies technically capable of meeting the Government's potential requirement. All Small Business companies with the capability and availability to perform the requirement under the applicable NAICS code are invited to submit a response to this notice. NORTH AMERICAN CLASSIFICATION SYSTEM (NAICS) CODE The NAICS code applicable to this requirement is 541990- All Other Professional, Scientific and Technical Serviceswith associated small business size standard of $15.0 million. BACKGROUND The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) was officially established in fiscal year 2012 to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS, one of 27 Institutes and Centers (ICs) at NIH, strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. The Therapeutics for Rare and Neglected Diseases (TRND) program at the National Center for Advancing Translational Sciences (NCATS) in the National Institutes of Health (NIH) supports pre-clinical development of therapeutic candidates intended to treat rare or neglected disorders, with the goal of enabling Investigational New Drug (IND) candidates. TRND projects are selected based on their potential to move forward into human trials and transform patient care for rare and neglected diseases. Each project has the potential for success and ability to teach important lessons about rare and neglected disease drug development. Plasmodium falciparum malaria remains a major threat to the public health, especially in tropical and subtropical areas of the world's poorest countries. The life cycle of Plasmodium falciparum malaria comprises an exogenous sexual phase with multiplication in certain mosquitoes corresponding to the vector of the disease and an endogenous asexual phase with multiplication in the human host. During a blood meal, a malaria-infected female Anopheles mosquito inoculates sporozoites into the human host. After several asexual cycles in the blood following the hepatic cycle, some merozoites can differentiate into sexual forms known as macro (female) or micro (male) gametocytes. This production of gametocytes from asexual parasites is named gametocytogenesis. Ingestion of these gametocytes by the invertebrate host allows for the following gametocytogenesis process and the continuation of the parasite cycle. Although the malaria illness is caused by the asexual blood stages, the presence of gametocytes is directly responsible for the infection of the anopheline vector, thus perpetuating the plasmodial cycle. Thus, identifying drugs which can kill gametocytes is an essential strategy in antimalarial drug development. Recently NCATS has identified a series of (quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-ones with gametocytes killing activity. Since similar compounds were reported as cancer treatments with potential adverse effects, it is important to measure our compound's inhibitory activity against common safety pharmacology targets so that we can develop a strategy to keep the gametocyte killing activity and reduce the safety-related attrition. PURPOSE AND OBJECTIVES The purpose of this potential requirement is to obtain contractor results of compound testing from profiling panels that provide early identification of significant off-target interactions for the optimization of safety margins of various compounds. This project is to determine percent inhibition values of 10 compounds in lead optimization and safety profiling panels using 44 selected targets and 2 compounds in lead optimization and safety profiling panels using 87 selected targests. PROJECT REQUIREMENTS This Small Business Sources Sought notice seeks responses from qualified sources that are capable of providing the following salient service requirements of this potential government requirement deemed as the essential features needing to be achieved. Offerors to this Sources Sought notice shall possess the capability of achieving the following general requirements: Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work below: 1.Determine percent inhibition values of 10 compounds in the lead optimization and safety profiling panels of 44 selected targets and lead optimization and safety profiling panels of 87 selected targets. 2.The selected targets shall be gathered in a cost-effective panel that brings together both robustness (each assay is HTS-compatible) and the strategic choice of information-rich targets in the drug discovery process. 3.Item description includes Assay mode using Single Point, 2 compounds, 1 concentration, 2 replicates, quantity two (2), 10 day turnaround time, batch consisting of default test Con. 10 uM. 4.Profiling panels used shall provide the early identification of significant off-target interactions for the optimization of safety margins required. Period of Performance Project Initiation Date: receipt of purchase order and the compounds Project Completion Date: 2 weeks after receipt of the compounds The projected award date is July 31, 2018. All compounds and testing results need to be completed no later than September 30, 2018. GOVERNMENT RESPONSIBILITIES NCATS will provide the compounds to be profiled. DELIVERY OR DELIVERABLES Reporting of results must be delivered electronically to NCATS within 2 weeks of receipt of compounds. CAPABILITY STATEMENT / INFORMATION SOUGHT Interested parties are expected to review this notice to familiarize itself with the requirements of this project. Failure to do so will be at your firm's own risk. Respondents must provide clear and convincing evidence of possessing the knowedge, skills, abilities and experience to successfully perform the requirements described in this announcement. Detailed past experience in implementing similar requirements to the requirement described in this announcement must be clearly delineated in any response provided. Respondents must provide clear and convincing documentation of their capability in providing analytical quality control and any other requirements and services specified in this notice. Respondents must provide a general overview of the respondents' opinions about the difficulty and /or feasibility of the potential requirement, and any information regarding innovative ideas or concepts. The Respondent must also provide information in sufficient detail of the respondents' (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc.) pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, CV's or references, if requested. The information submitted must be must be in and outline format that addresses each of the elements of the product requirement. A cover page and an executive summary may be included but is not required. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response MUST reference the solicitation number and be submitted electronically to Mr. Hunter Tjugum at hunter.tjugum@nih.gov prior to the closing date specified in this announcement. The response must be received on or before the closting date/time specified in this announcement. CONCLUDING STATEMENTS Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/NIHDA201800280/listing.html)
- Record
- SN04969506-W 20180628/180626231228-a481214fb98ed8c409d7b82983b62619 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |